Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CITIUS ONCOLOGY, INC.CTOR · Entity 6935 | Director | September 19, 2025 | December 22, 2025 |
| Citius Pharmaceuticals, Inc.CTXR · Entity 7778 | Director | November 07, 2024 | November 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CITIUS ONCOLOGY, INC.
Report date September 19, 2025 · Filed December 22, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 300,000 |
Reported balance
After 2025-09-19 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-09-19 · Grant · Acquired 300,000 · Balance 300,000 F1: Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
Citius Pharmaceuticals, Inc.
Report date November 07, 2024 · Filed November 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2034-11-07 | Direct | 125,000 |
Reported balance
After 2024-11-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-11-07 · Grant · Acquired 125,000 · Balance 125,000 F1: The options were granted on November 7, 2024. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $0.69 · Expires 2034-03-12 | Direct | 75,000 |
Reported balance
Holding disclosure · report date 2024-11-07 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 75,000 F2: The options are vested in full and exercisable immediately. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on November 7, 2024. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date.
F2: The options are vested in full and exercisable immediately.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 19, 2025 Filed Sep 23, 2025 16:10 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-090615 · ownership.xml · nonDerivative · entry 1 Smith Robert Joseph · CIK 0002008764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 F1 · shares: Represents restricted stock awards granted on September 19, 2025. The shares will vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. Read SEC document |
| September 19, 2025 Filed Dec 1, 2025 16:10 UTC Amendment | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-116676 · ownership.xml · nonDerivative · entry 1 Smith Robert Joseph · CIK 0002008764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 F1 · shares: Represents restricted stock awards granted on September 19, 2025. The shares will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. Read SEC document |
| September 19, 2025 Filed Dec 22, 2025 16:10 UTC Amendment | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-124532 · ownership.xml · nonDerivative · entry 1 Smith Robert Joseph · CIK 0002008764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 F1 · shares: Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 16:08 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001213900-24-109301 · ownership.xml · derivative · entry 1 Smith Robert Joseph · CIK 0002008764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-12-12 F1 · derivative.exercise_date: The options were granted on December 12, 2024. The options will vest 100% on the one-year anniversary of the grant date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 17:00 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantStock Option (Right to Purchase Common Stock) · Derivative | 125,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001213900-24-096894 · ownership.xml · derivative · entry 1 Smith Robert Joseph · CIK 0002008764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-11-07 F1 · derivative.exercise_date: The options were granted on November 7, 2024. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 16:06 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantStock Option (Right to Purchase Common Stock) · Derivative | 75,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001213900-24-023487 · ownership.xml · derivative · entry 1 Smith Robert Joseph · CIK 0002008764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-03-12 F1 · derivative.exercise_date: The options were granted on March 14, 2024, with a Vesting Commencement Date of March 12, 2024, the date of the Optionee's election to the Board of the Company. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.